Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) traded up 8.7% during mid-day trading on Friday . The stock traded as high as $6.37 and last traded at $6.28, with a volume of 69,919 shares. The stock had previously closed at $5.78.

Several equities research analysts have issued reports on the stock. Needham & Company LLC assumed coverage on shares of Aeglea Biotherapeutics in a research note on Monday, May 9th. They set a “buy” rating and a $18.00 target price on the stock. Zacks Investment Research raised shares of Aeglea Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 17th.

The company’s market cap is $83.82 million. The company has a 50-day moving average of $5.03 and a 200-day moving average of $6.50.

Aeglea Biotherapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Equities research analysts expect that Aeglea Biotherapeutics Inc. will post ($4.77) earnings per share for the current year.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.